Similar to HLA-DR, PBMCs from MS responded more pronouncedly in comparison with HDs: the percentage of CD80+ cells increased from ~1 to 4.8–8.1% in MS and 2.4–3.9% in HD in case of exposure to GK16 and QR24, respectively. This evidence concerns the gene CD80 and myeloid sarcoma.